Chs 828

Manufactured by Cayman Chemical

CHS-828 is a chemical reagent used in research and laboratory settings. It is a solid compound that functions as a chemical building block or intermediate for further synthesis and experimentation. The core purpose of CHS-828 is to serve as a versatile chemical tool for researchers and scientists conducting various types of chemical analysis and development.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using chs 828

Evaluation of Anticancer Drug Synergy

Check if the same lab product or an alternative is used in the 5 most similar protocols

CCRF-CEM and MDA MB231 cells were treated with FK866, CHS-828 (200484-11-3, Cayman Chemical), oligomycin A (75351, Sigma), 2-deoxyglucose (D8375, Sigma), GSK2837808A (GSK) (5189, Tocris), JPH203 (a selective L-type amino acid transporter), and l-asparaginase (11185, Sigma) for 48 h. JPH203 was kindly obtained from Dr. Peyron [30 (link)]. In vitro drug sensitivity was assessed by the colorimetric methyl-thiazolyltetrazolium (MTT) assay (sigma), XTT proliferation kit (sigma), and OZBlue Cell Viability kit (OZbiosciences). Combination treatment of FK866 with JPH203 was performed and 48 h after combination treatment, Cell viability was determined using XTT assay (Invitrogen) and DAPI staining. Percentage of cell death was subjected for drug combination analysis as described by combination index (CI). CI was analyzed using CompuSyn software V1.0 by the method of Chou and Talalay [31 (link)]. CI < 1 indicates drug synergistic effect, CI > 1 indicates drug antagonistic effect, and CI = 1 indicates drug additive effect.

Thongon N., Zucal C., D’Agostino V.G., Tebaldi T., Ravera S., Zamporlini F., Piacente F., Moschoi R., Raffaelli N., Quattrone A., Nencioni A., Peyron J.F, & Provenzani A. (2018). Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA. Cancer & Metabolism, 6, 1.

+ Open protocol

+ Expand

Cell Viability Assay for Drug Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols

PAR and RES cells were treated with FK866 (sc-205325, Santa Cruz Biotechnology), CHS-828 (200484-11-3, Cayman Chemical), verapamil (V4629, Sigma), antimycin A (A8674, Sigma), 5-FU (F6627, Sigma), cisplatin (PHR1624, Sigma), olaparib (HY-10162, MedChemExpress), UK5099 (5048170002, Sigma) and rosiglitazone (R2408, Sigma) for 48 h. In vitro drug sensitivity was assessed by OzBlue Cell Viability kit (OzBiosciences) after 2 h of incubation, according to the manufacturer instructions.

Carreira A.S., Ravera S., Zucal C., Thongon N., Irene C., Astigiano C., Bertola N., Buongiorno A., Roccuzzo M., Bisio A., Pardini B., Nencioni A., Bruzzone S, & Provenzani A. (2023). Mitochondrial rewiring drives metabolic adaptation to NAD(H) shortage in triple negative breast cancer cells. Neoplasia (New York, N.Y.), 41, 100903.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!